These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2566953)

  • 21. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?
    Savory J; Exley C; Forbes WF; Huang Y; Joshi JG; Kruck T; McLachlan DR; Wakayama I
    J Toxicol Environ Health; 1996 Aug; 48(6):615-35. PubMed ID: 8772802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental aluminum encephalomyelopathy. Relationship to human neurodegenerative disease.
    Rao JK; Katsetos CD; Herman MM; Savory J
    Clin Lab Med; 1998 Dec; 18(4):687-98, viii. PubMed ID: 9891607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy.
    Reinikainen KJ; Soininen H; Riekkinen PJ
    J Neurosci Res; 1990 Dec; 27(4):576-86. PubMed ID: 1981917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropathologic, neurochemical and immunocytochemical characteristics of aluminum-induced neurofilamentous degeneration.
    Pendlebury WW; Beal MF; Kowall NW; Solomon PR
    Neurotoxicology; 1988; 9(3):503-10. PubMed ID: 3200512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central cholinergic activity in aluminum-induced neurofibrillary degeneration.
    Hetnarski B; Wisniewski HM; Iqbal K; Dziedzic JD; Lajtha A
    Ann Neurol; 1980 May; 7(5):489-90. PubMed ID: 7396428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A postmortem study of amino acid neurotransmitters in Alzheimer's disease.
    Ellison DW; Beal MF; Mazurek MF; Bird ED; Martin JB
    Ann Neurol; 1986 Nov; 20(5):616-21. PubMed ID: 2878639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranuclear aluminum accumulation in chronic animals with experimental neurofibrillary changes.
    Uemura E
    Exp Neurol; 1984 Jul; 85(1):10-8. PubMed ID: 6734771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An immunocytochemical comparison of cytoskeletal proteins in aluminum-induced and Alzheimer-type neurofibrillary tangles.
    Munoz-Garcia D; Pendlebury WW; Kessler JB; Perl DP
    Acta Neuropathol; 1986; 70(3-4):243-8. PubMed ID: 3532685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aluminum-induced neurotoxicity and oxidative damage in rabbits: protective effect of melatonin.
    Abd-Elghaffar SKh; El-Sokkary GH; Sharkawy AA
    Neuro Endocrinol Lett; 2005 Oct; 26(5):609-16. PubMed ID: 16264393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synaptic density in chronic animals with experimental neurofibrillary changes.
    Uemura E; Ireland WP
    Exp Neurol; 1984 Jul; 85(1):1-9. PubMed ID: 6539712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1988 Feb; 23(2):105-14. PubMed ID: 2897822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurofibrillary lesions in experimental aluminum-induced encephalopathy and Alzheimer's disease share immunoreactivity for amyloid precursor protein, A beta, alpha 1-antichymotrypsin and ubiquitin-protein conjugates.
    Huang Y; Herman MM; Liu J; Katsetos CD; Wills MR; Savory J
    Brain Res; 1997 Oct; 771(2):213-20. PubMed ID: 9401741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quantitative autoradiographic study of [3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
    Bonkale WL; Cowburn RF; Ohm TG; Bogdanovic N; Fastbom J
    Brain Res; 1999 Feb; 818(2):383-96. PubMed ID: 10082824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aluminium, neurofibrillary degeneration and Alzheimer's disease.
    Crapper DR; Krishnan SS; Quittkat S
    Brain; 1976 Mar; 99(1):67-80. PubMed ID: 963531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disrupted retention of the classically conditioned nictitating membrane response in rabbits with aluminum-induced neurofibrillary degeneration.
    Solomon PR; Pingree TM; Baldwin D; Koota D; Perl DP; Pendlebury WW
    Neurotoxicology; 1988; 9(2):209-21. PubMed ID: 3205431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1991 Feb; 29(2):162-7. PubMed ID: 1672808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
    Walton JR
    J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Brain lesions, pathogenic and etiologic hypotheses of Alzheimer's disease].
    Dessi F; Colle MA; Hauw JJ; Duyckaerts C
    Rev Prat; 1998 Nov; 48(17):1873-8. PubMed ID: 9854388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The failing brain.
    Bowen DM; Davison AN
    J Chronic Dis; 1983; 36(1):3-13. PubMed ID: 6129258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunocytochemical studies of neurofilament antigens in the neurofibrillary pathology induced by aluminum.
    Troncoso JC; Sternberger NH; Sternberger LA; Hoffman PN; Price DL
    Brain Res; 1986 Feb; 364(2):295-300. PubMed ID: 3512034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.